Follow The Filings

Krensavage Asset Management LLC Michael Krensavage

New York, NY 21 processed 13Fs on this site, 2021 Q3 to 2026 Q2

  • $263M
  • 18 holdings
  • 2026 Q2
  • +2.7% QoQ
  • Top 5 64.7%

Portfolio

2026 Q2, filed 8/13/2026, top 12 of 18 holdings

Top 5 64.7%, top 10 89.4%

  1. ENTA, Enanta Pharmaceuticals 15.9%
  2. JAZZ, Jazz Pharmaceuticals 15.4%
  3. UTHR, United Therapeutics 14.3%
  4. BMRN, Biomarin Pharmaceutical 11.4%
  5. EXEL, Exelixis 7.7%
  6. ABT, Abbott Laboratories 6.9%
  7. SNY, Sanofi-Adr 5.2%
  8. SUPN, Supernus Pharmaceuticals 5.0%
  9. RARE 4.9%
  10. VNDA, Vanda Pharmaceuticals 2.7%
  11. BNTX, Biontech Se-Adr 2.1%
  12. GSK 1.9%
  13. Other 6.6%

AUM over time

2026 Q2 $263M +2.7% QoQ
2021 Q3: $319M 2021 Q3: $319M
Q3 2021
2021 Q4: $288M, −9.7% QoQ 2021 Q4: $288M, −9.7% QoQ
Q4
2022 Q1: $290M, +0.7% QoQ 2022 Q1: $290M, +0.7% QoQ
Q1 2022
2022 Q2: $302M, +4.1% QoQ 2022 Q2: $302M, +4.1% QoQ
Q2
2022 Q3: $314M, +4.0% QoQ 2022 Q3: $314M, +4.0% QoQ
Q3
2022 Q4: $324M, +3.2% QoQ 2022 Q4: $324M, +3.2% QoQ
Q4
2023 Q1: $329M, +1.5% QoQ 2023 Q1: $329M, +1.5% QoQ
Q1 2023
2023 Q2: $316M, −4.0% QoQ 2023 Q2: $316M, −4.0% QoQ
Q2
2023 Q3: $272M, −13.9% QoQ 2023 Q3: $272M, −13.9% QoQ
Q3
2023 Q4: $282M, +3.7% QoQ 2023 Q4: $282M, +3.7% QoQ
Q4
2024 Q1: $226M, −19.9% QoQ 2024 Q1: $226M, −19.9% QoQ
Q1 2024
2024 Q2: $218M, −3.5% QoQ 2024 Q2: $218M, −3.5% QoQ
Q2
2024 Q3: $178M, −18.3% QoQ 2024 Q3: $178M, −18.3% QoQ
Q3
2024 Q4: $169M, −5.1% QoQ 2024 Q4: $169M, −5.1% QoQ
Q4
2025 Q1: $181M, +7.1% QoQ 2025 Q1: $181M, +7.1% QoQ
Q1 2025
2025 Q2: $189M, +4.4% QoQ 2025 Q2: $189M, +4.4% QoQ
Q2
2025 Q3: $235M, +24.3% QoQ 2025 Q3: $235M, +24.3% QoQ
Q3
2025 Q4: $283M, +20.4% QoQ 2025 Q4: $283M, +20.4% QoQ
Q4
2026 Q1: $256M, −9.5% QoQ 2026 Q1: $256M, −9.5% QoQ
Q1 2026
2026 Q2: $263M, +2.7% QoQ 2026 Q2: $263M, +2.7% QoQ
Q2

Book

2021 Q4 2021 Q3, filed 15 Feb, long equity only

Download CSV Download Excel All activity
UTHR, United Therapeutics 15.35% Reduce −1.2% 204,812 $216.08 $44M −2,475 +$6M
REGN, Regeneron 15.13% Reduce −5.6% 69,080 $631.51 $44M −4,063 −$640K
ENTA, Enanta Pharmaceuticals 14.63%, was 16.69% Reduce −39.8% 564,102 $74.78 $42M −372,675 −$11M
MCK, McKesson 13.49% Reduce −5.0% 156,424 $248.57 $39M −8,167 +$6.1M
ALKS, Alkermes 11.64% Add +0.1% 1,442,965 $23.26 $34M +998 −$11M
EXEL, Exelixis 9.87%, was 6.63% Add +55.7% 1,557,119 $18.28 $28M +557,119 +$7.3M
Holding 9.37%, was 10.89% Reduce −1.2% 538,967 $50.11 $27M −6,616 −$7.7M
BIIB, Biogen 8.58%, was 9.16% Reduce −0.1% 103,053 $239.92 $25M −149 −$4.5M
Eagle Pharmaceuticals 1.88%, was 1.89% Reduce −1.2% 106,487 $50.92 $5.4M −1,286 −$590K
Nextcure 0.06% Add +0.3% 31,027 $5.99 $186K +100 −$22K

Exits / last held

Gone since 2021 Q3, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
Surgalign 2.17% Exit 0 $1.09 $6.9M −6,332,945 −$6.9M
Invacare 1.33% Exit 0 $4.76 $4.2M −891,259 −$4.2M
TVTX, Travere Therapeutics 1.04% Exit 0 $24.25 $3.3M −137,203 −$3.3M

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2021 Q3. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

20 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 18 $263M +2.7% 13F-HR 8/13/2026 000160925126000005
2026 Q1 20 $256M −9.5% 13F-HR 5/15/2026 000160925126000004
2025 Q4 18 $283M +20.4% 13F-HR 2/18/2026 000160925126000003
2025 Q3 17 $235M +24.3% 13F-HR 11/17/2025 000160925125000007
2025 Q2 15 $189M +4.4% 13F-HR 8/15/2025 000160925125000006
2025 Q1 14 $181M +7.1% 13F-HR 5/15/2025 000160925125000004
2024 Q4 12 $169M — RESTATEMENT 2/18/2025 000160925125000002
2024 Q4 12 $169M −5.1% 13F-HR 2/18/2025 000160925125000001
2024 Q3 13 $178M −18.3% 13F-HR 11/15/2024 000164227424000006
2024 Q2 13 $218M −3.5% 13F-HR 8/15/2024 000160925124000006
2024 Q1 12 $226M −19.9% 13F-HR 5/15/2024 000160925124000005
2023 Q4 12 $282M +3.7% 13F-HR 2/14/2024 000160925124000002
2023 Q3 12 $272M −13.9% 13F-HR 11/15/2023 000160925123000005
2023 Q2 12 $316M −4.0% 13F-HR 8/11/2023 000160925123000004
2023 Q1 12 $329M +1.5% 13F-HR 5/16/2023 000160925123000003
2022 Q4 12 $324M +3.2% 13F-HR 2/15/2023 000160925123000001
2022 Q3 14 $314M +4.0% 13F-HR 11/15/2022 000160925122000005
2022 Q2 14 $302M +4.1% 13F-HR 8/16/2022 000160925122000004
2022 Q1 13 $290M +0.7% 13F-HR 5/17/2022 000160925122000003
2021 Q4 10 $288M −9.7% 13F-HR 2/15/2022 000160925122000002
2021 Q3 13 $319M — 13F-HR 11/16/2021 000160925121000006

About

Krensavage Asset Management LLC

21 processed 13Fs on this site, 2021 Q3 to 2026 Q2

Entity
Krensavage Asset Management LLC
Notable person
Michael Krensavage
SEC filing name
Krensavage Asset Management, LLC
Location
New York, NY
All SEC filings
View on sec.gov